Abstract: The invention relates to the field of medical biotechnology. Specifically, the present invention relates to a fusion protein containing an anti-interleukin-17 antibody and a tumor necrosis factor receptor extracellular region, a polynucleotide encoding the fusion protein, a vector comprising the polynucleotide, a host cell comprising the polynucleotide or the vector, and the use of the fusion protein for the treatment, prevention, and/or diagnosis of a related disease in an individual.
Type:
Grant
Filed:
November 6, 2018
Date of Patent:
June 6, 2023
Assignees:
BEIJING BEYOND BIOTECHNOLOGY CO., LTD, HANGZHOU POLYMED BIOPHARMACEUTICALS, INC.